Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Sunitinib has been shown to be effective in advanced pancreatic neuroendocrine tumors (PNETs) but it is not well known how dose-intensity and treatment time influence the results.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Jimenez-Fonseca P, Solis Hernandez M, Fernandez del Valle A, Garcia-Carbonero R, Matos I,
Keywords: PNET, sunitinib, dose-intensive, progression-free survival,
Introduction: Response Evaluation Criteria In Solid Tumors (RECIST) are not presumably the most optimal option for predicting the benefit of antiangiogenic drugs in neuroendocrine tumors (NETs), given that tumor shrinkage is not frequent, and qualitative changes in tumor tissues are to be expected.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Carmona-Bayonas A, Fernandez del Valle A, Solis M, Matos I, Garcia-Carbonero R,
Keywords: CHOI criteria, pancreatic neuroendocrine tumor, RECIST, response, survival,
Introduction: NENs are rare and global European epidemiologic data are only based on national or compilation of national registries. So, there is a need for comprehensive homogenous information
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Borbath I
Authors: Borbath I, Pape U, Garcia-Carbonero R, Sedláčková E, Kollár A,
Keywords: ENETS registry, Europe,
Introduction: There are several effective drugs for advanced pancreatic neuroendocrine tumors (PNETs) but the right treatment sequence hasn’t been defined yet.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Solis-Hernandez M
Authors: Solis-Hernandez M, Calvo-Temprano D, Carmona-Bayonas A, García-Carbonero R, Custodio A,
Keywords: Sunitinib, targeted therapies,
Introduction: Sst5TMD4, which is derived from a non-canonical splicing process of sst5 receptor, is overexpressed in several endocrine tumors and associated with a worse prognosis.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Diaz Perez A, Martínez-Fuentes A, García-Carbonero R, Luque R, Jimenez-Fonseca P,
Keywords: somatostatin receptor, neuroendocrine tumors,